GLP-1 Outcomes — proposed research program

Proposed: not enrolling

Research question

How can future observational research describe metabolic outcomes, tolerability, and treatment persistence during clinician-directed incretin therapy?

Proposed scope

This proposed program would examine how clearly defined clinical outcomes change over time in a characterized population. A useful design would distinguish weight, glycemic measures, patient-reported function, treatment persistence, and adverse events rather than combining them into a single success label. It would identify the actual medicine and formulation and record relevant co-interventions.

Methods to develop

A future protocol could define baseline disease, prior treatment, concomitant medicines, follow-up windows, and reasons for discontinuation. Outcome definitions and the handling of missing follow-up would need to be specified before analysis. Treatment choice in an observational study can be related to disease severity, access, and clinician preference, so a simple before-and-after comparison would not establish causation.

Scientific purpose

The educational contribution would be a shared framework for asking reproducible questions and interpreting evidence across sites. Any comparative analysis would need an explicit strategy for confounding and consistent outcome measurement. The program would observe appropriate clinical care rather than assign experimental treatment through a public website.

Current status

This is an editorial proposal for discussion, not an active study or approved registry. There is no enrollment and no patient-data collection. Investigators, sites, partners, funding, ethics approval, and study dates have not been established by this description. A protocol, ethics and data-protection review, and appropriate institutional authorization would be required before any research activity involving participants.

References informing the proposal

• Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52. DOI: 10.1007/BF02427280. PMID: 3514343.
• Nauck MA, Müller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66(10):1780-1795. DOI: 10.1007/s00125-023-05956-x. PMID: 37430117.
• Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. DOI: 10.1016/j.cmet.2018.03.001. PMID: 29617641.
• Novo Nordisk. WEGOVY (semaglutide). U.S. prescribing information. DailyMed, National Library of Medicine.
• Eli Lilly. ZEPBOUND (tirzepatide). U.S. prescribing information, version 38. DailyMed, National Library of Medicine.